文献综述：磷脂遮盖的PEI基奈米各种载体中用体内的siRNA*多药耐药性*网页链接：//www.nature.com/articles/gt201497写作者：埃塞克斯郡南方G纳瓦罗P·萨巴钱达尼，条理膜M Trivedi，S Movassaghian＆副总经理裁托尔奇林节选：三维线瘤中P-糖血清过表述介导的多药抗药理帮助性(MDR)是各种各样手术失利的常见的因素。本深入分析分析考评了磷脂突显的分低子量聚丁二烯亚胺(DOPE-PEI)納米级技术质粒用以冠状动脉卸料*P-糖血清siRNA至*的效果好，从而对方是监测乳房增生癌的MDR。首选，我深入分析分析了DOPE-PEI納米级技术质粒的生物工程占比及PEG表层在皮内乳房增生*3d模型中的帮助。打瘦脸针后四小时英文，PEG化质粒经过减弱的透水性性和限制出境定律，在三维线瘤中掌握了8%的打瘦脸针服用量(ID)，伴随PEG介导的循环系统期限廷长，在血清中掌握了22%的ID。前者，我决定了DOPE-PEI/siRNA介导的P-gp上涨联合技术阿霉素(Dox)手术在MCF-7/MDR异种移值瘤中的效用和危险系数高性。每季度打瘦脸针siRNA納米级技术药品和Dox，继续有5周，使*对原有失败服用量的Dox诞生过敏性，并使*面积与差表组相比之上涨小了三到五倍。这一对Dox效用的可以改善归因于DOPE-PEI药品介导的切掉*中特殊的队列非特异聊天P-gp上涨。

Multidrug resistance (MDR) mediated by P-glycoprotein overexpression in solid tumors is a major factor in the failure of many forms of chemotherapy. Here we evaluated phospholipid-modified, low-molecular-weight polyethylenimine (DOPE-PEI) nanocarriers for intravenous delivery of anti-P-pg siRNA to tumors with the final goal of modulating MDR in breast cancer. First, we studied the biodistribution of DOPE-PEI nanocarriers and the effect of PEG coating in a subcutaneous breast tumor model. Four hours postinjection, PEGylated carriers showed an 8% injected dose (ID) accumulation in solid tumor via the enhanced permeability and retention effect and 22% ID in serum due to a prolonged, PEG-mediated circulation. Second, we established the therapeutic efficacy and safety of DOPE-PEI/siRNA-mediated P-gp downregulation in combination with doxorubicin (Dox) chemotherapy in MCF-7/MDR xenografts. Weekly injection of siRNA nanopreparations and Dox for up to 5 weeks sensitized the tumors to otherwise non-effective doses of Dox and decreased the tumor volume by threefold vs controls. This therapeutic improvement in response to Dox was attributed to the significant, sequence-specific P-gp downregulation in excised tumors mediated by the DOPE-PEI formulations.上海pg电子娱乐游戏app 海洋生物出具关于设备：DSPE-PyreneDSPE-ThiolDSPE-PEG-GE11(二硬脂酰基磷脂酰酒精胺-聚乙二醇-*受损细胞皮层种子发芽细胞因子EGFR靶向治疗肽)DSPE-PEG-HisDSPE-PEG-cRGD(二硬脂酰基磷脂酰酒精胺-聚乙二醇-数据整合素靶点环肽)ALC-0315DOPE-PEG-MalDSPE-PEG-M2pepDSPE-PEG-cisplatinDSPEGPC3靶向药物肽-PEG-DSPE上述小文章项目的来源常见刊物或专著，假如有图片侵权请取得联系小编删除文件！